ProHance Gadoteridol Injection

1. Indications and Usage
Gadoteridol injection is indicated for intravascular injection to enhance the contrast of lesions in the brain, spine, and other areas of the body in magnetic resonance imaging (MRI).
2. Dosage and Administration
Recommended Dosage: The recommended dose for adults and children is 0.1 mmol/kg (0.1 mL/kg) administered intravenously.
Administration: The injection should be administered as a rapid intravenous bolus or injection.
Repeat Dosage: If a repeat dose is required, at least 24 hours should elapse between administrations.
3. Mechanism of Action
Gadoteridol contains paramagnetic gadolinium ions. In an external magnetic field, these ions alter the relaxation times of nearby hydrogen protons, thereby increasing the signal intensity on T1-weighted MRI images and enhancing the visibility of vascularized tissues and lesions.
4. Safety and Warnings
Nephrogenic Systemic Fibrosis (NSF): Gadolinium-based contrast agents (GBCAs) pose a risk of NSF in patients with acute or severe chronic renal impairment (GFR <30 mL/min/1.73 m²) or acute renal failure.
Hypersensitivity: Serious and rare hypersensitivity reactions, including anaphylaxis, may occur. Life-support equipment should be readily available during administration.
Gadolinium Retention: Trace amounts of gadolinium have been found to persist in the brain, bones, and other tissues long after administration, although the clinical significance of this retention is currently unknown.
5. Adverse Reactions and Clinical Research
Common Adverse Reactions: Headache, dizziness, nausea, and injection site reactions (pain, sensation of cold, or warmth) are the most frequently reported adverse reactions.
Clinical Research: Pivotal clinical trials have demonstrated high efficacy and safety in enhancing diagnostic confidence for various intracranial and spinal pathologies.
6. Drug Interactions
Beta-blockers and Vasopressors: These drugs may decrease the efficiency of cardiovascular compensatory mechanisms during systemic disturbances.
General: No formal pharmacokinetic drug interaction studies have been conducted.
7. Pharmaceutical Information
Composition: The active ingredient is gadoteridol, a gadolinium chelate.
Appearance: A clear, colorless to pale yellow liquid for intravenous use.
Storage: Store at controlled room temperature. The solution should be inspected visually for particulate matter and discoloration prior to administration.